Use of transient elastography to predict de novo recurrence after radiofrequency ablation for XXXX .

@entity1 @entity82 @entity5 @entity648 @entity409 @entity1575 @entity157
BACKGROUND/PURPOSE: @entity409 ( @entity409 ) measurement using transient elastography can accurately assess the degree of @entity1575 , which is associated with the risk of the development of @entity157 ( @entity157 ). We investigated whether @entity409 values could predict @entity157 de novo recurrence after radiofrequency ablation (RFA). METHODS: This retrospective, multicenter study analyzed 111 @entity1 with @entity157 who underwent RFA and @entity409 measurement using transient elastography between May 2005 and April 2011. All @entity1 were followed until March 2013 to monitor for @entity157 recurrence. RESULTS: This study included 76 @entity1 and 35 @entity1 with a mean age of 62.4 years, and the mean @entity409 value was 21.2 kPa. During the follow-up period (median 22.4 months), 47 (42.3%) @entity1 experienced @entity157 de novo recurrence, and 18 (16.2%) died. @entity1 with recurrence had significantly more frequent liver @entity82 , more frequent history of previous treatment for @entity157 , higher total @entity648 , larger spleen size, larger total @entity5 size, higher @entity5 number, higher @entity409 values, and lower platelet counts than those without recurrence (all P<0.05). On multivariate analysis, together with previous anti- @entity157 treatment history, @entity1 with @entity409 values >13.0 kPa were at significantly greater risk for recurrence after RFA, with a hazard ratio (HR) of 3.115 (95% confidence interval [CI], 1.238-7.842, P<0.05). Moreover, @entity409 values independently predicted the mortality after RFA, with a HR of 9.834 (95% CI, 1.148-84.211, P<0.05), together with total @entity648 . CONCLUSIONS: Our data suggest that @entity409 measurement is a useful predictor of @entity157 de novo recurrence and overall survival after RFA.
